drugset / Trial / NCT00742469

Rifaximin for Prevention of Travellers' Diarrhea

NCT00742469

Phase 3 Completed 210 enrolled Bausch Health Americas, Inc.
RandomizedParallel-groupDouble-blindPrevention

Summary

The purpose of this study is to determine if 600 mg of rifaximin, taken once a day for 14 days by healthy subjects, is safe and effective for the prevention of travellers' diarrhea compared to placebo.

Timeline

Start
2005-06
Primary completion
2005-09
Completion
2007-04

Drugs

EvaluationDrugModalityDoseRoute
Comparator Rifaximin Other / unclassified 600 mg

Indications